Immunovant (IMVT) Reports Wider-Than-Expected Loss in Q3 Posted byZacks Equity Research February 7, 2022 Leave a comment on Immunovant (IMVT) Reports Wider-Than-Expected Loss in Q3 Immunovant’s (IMVT) earnings miss estimates in fiscal third-quarter, which ended on Dec 31, 2021. Focus remains on lead pipeline candidate batoclimab.